Tuberculosis demand forecast 2014-2016 Brussels, 10 April 2013 Dr Mario Raviglione Director, Stop TB Department World Health Organization, Geneva, Switzerland.

Slides:



Advertisements
Similar presentations
External Financing for Health Care: Takemi Working Group Recommendations to G8 Ravi P. Rannan-Eliya ECOSOC Annual Ministerial Review – Regional Ministerial.
Advertisements

The Effectiveness of Global Health Partnerships Findings and Lessons from a World Bank Evaluation of Global Health Programs Uma Lele April 14, 2005.
W. J. Fenton MD, FRCPC, FACP Clinical Professor of Medicine, U of S Tuberculosis Consultant Tuberculosis: Global Canada Saskatchewan.
Dr. E. Anne Peterson, MD, MPH Assistant Administrator, Bureau for Global Health, USAID Sustainable Investment and Donor Coordination Stop TB Partners Forum.
AIDS2031 LONG TERM COSTS AND FINANCING FOR HIV/AIDS ICAAP 12 AUGUST 2009 BALI INDONESIA Farzana Muhib, Results for Development Institute.
ADDING IT UP The costs and benefits of investing in family planning and maternal and newborn health.
Achieving a ‘Grand Convergence’ in Global Health Chair: Richard Feachem, University of California, San Francisco Presenter: Dean Jamison, University of.
REPORT HIGHLIGHTS “Children should be the first to benefit from our successes in defeating HIV, and the last to suffer from our failures.” Anthony Lake,
 Global Strategy Meeting – January 2013, Amsterdam Global Fund Advocates Network.
Global Fund Replenishment October 3, 2013 RESULTS the power to end poverty.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
Technical Advisory Group meeting, WHO/WPRO
What, Where, How and Action Steps… XDR-TB
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
Zero TB deaths among PLHIV: what are the gaps and what is missing? Haileyesus Getahun Stop TB Department World Health Organisation, Geneva. Reaching Zero.
-Innovative Financing for Low Income Countries Providing Public Goods and Infrastructure Akbar Noman IPD, Columbia.
The Global Plan to Stop TB, (1)
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
Public-Private Mix (PPM) for TB Control in Global Fund grants Scope and significance SS Lal *, Mukund Uplekar #, Itamar Katz*, Knut Lonnroth #, Ryuichi.
1 New Funding Model Key features and implementation Inter-Agency Meeting 5-7 March 2014 Linda Mafu, Head Political and Civil Society Advocacy Department,
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
THE FIGHT TO STOP TB WHAT ARE WE FIGHTING? TUBERCULOSIS: THE WORLD’S NO. 1 KILLER AMONG CURABLE, INFECTIOUS DISEASES But there is hope PEOPLE WHO HAVE.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
Overview of New Funding Model May 17, 2013 Astana, Kazakhstan.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps…
Worldwide Importance of Certain Diseases LESSON OBJECTIVE: Discuss the global impact of malaria, HIV/AIDS and TB.
Analysis of Global Fund Support for Health Systems Strengthening Emily Trautner Geneva, Switzerland October 1, 2010.
World TB Day 2000 Forging New Partnerships to Stop TB Produced by the [ Stop TB Initiative ] Coordinating Team: WHO.
Session 11: MDR & XDR-TB: How Can Business Help Stem the Tide?
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
Ebola: Lessons Learned & Future Opportunities Ruby Sandhu-Rojon Deputy Director, Africa Bureau United Nations Development Programme.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
TB Public Private Partnerships Opportunity or Risk? Cheri Vincent Senior Public Health Advisor USAID June 3, 2008.
Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva, Switzerland TB prevention, care and control, : Framing global and WHO strategic.
Moving ahead with the Stop TB Strategy: where are we today? Dr Mario Raviglione Director, WHO Stop TB Department Joint Meeting of Core Teams and High Burden.
Chapter 19 Global Population Projections. Predicting the Future Many attempts using economic forecasting, political forecasting, and forecasting using.
Efficiency, Effectiveness, and Financial Sustainability: The Importance of Country Ownership Dr Bernhard Schwartländer UNAIDS.
MDG 6: Combat HIV/AIDS and other diseases. Where are we…  Regionally, “on track” for MDG-6 (only a few countries are progressing slowly or show no progress)
Abt Associates Inc. In collaboration with: I Aga Khan Foundation I Bitrán y Asociados I BRAC University I Broad Branch Associates I Deloitte Consulting,
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
OECD Trade Facilitation Indicators Transforming border bottlenecks into global gateways Harnessing Trade for Growth in the Mediterranean UN-PAM conference.
Fifteenth Board Meeting Geneva, April 2007 Partners in Impact Results Report Global Fund Board Meeting Geneva, April 2007.
Tuberculosis - the opportunity in our lifetime Dr. Lucica Ditiu | Executive Secretary | Stop TB Partnership 09.April.2013 | Brussels, Belgium.
The HIV Response Where are we now?
Resource Availability for HIV, Overview of the financing situation
Community Representative Update
financial requirements
Charting a new course for HIV and health in Africa:
TUBERCULOSIS, TB/HIV & MDR-TB
La tubercolosi nel terzo millennio
Stop TB Partnership Secretariat (TBP)
By: Dr Mirzaei.
8-9 August 2009, Bali, Indonesia
Stop TB Partnership Secretariat (TBP) M. Espinal, Executive Secretary
TB-HIV Last updated: November 2018.
Key issues in DOTS implementation
Funding gaps to realize the Global Plan to End TB
Update on HIV and TB situation in SEAR Dr Mukta Sharma RA HIV TB HEP WHO SEARO Global Fund , South-East Asia Constituency Meeting, April 2018,
July 21, 2016 Potential Domestic Source Financing for Scaled Up Antiretroviral Therapy in 97 Countries, 2016–2020 Arin Dutta, Catherine Barker, and Ashley.
TB Strategy & Health Systems (TBS) TB Monitoring & Evaluation (TME)
Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002–11, and requirements.
Goal, Objectives, Expected Outcomes
5th DEWG meeting Conclusions
Geneva, Switzerland June 2002
A Time of Commitments and Actions to accelerate action to End TB
5th edition NTP MANUAL OF PROCEDURES Chapter 1: Introduction
Presentation transcript:

Tuberculosis demand forecast Brussels, 10 April 2013 Dr Mario Raviglione Director, Stop TB Department World Health Organization, Geneva, Switzerland Photo: Riccardo Venturi

Funding required US$ billions TB/HIV excl. ART Rapid diagnostics, related laboratory strengthening MDR-TB treatment Largest investment needed for DOTS but, largest increase needed for: rapid diagnostics/labs and MDR-TB DOTS Available funds (2011)

Funding needs + gaps, by income group 37 low-income (LICs) 54 lower-middle income (LMICs)27 upper-middle income (UMICs) Gap : $1.3 b Big relative gap (~60%) in LICs LMICs assumed to increase domestic funding. IF NOT much bigger gap Total funding gap US$ 4.3 billion Gap : $1.4 b US$ billions Gap : $1.6 b

Biggest gaps in Africa: 59% of total gap, Africa Asia Rest of the World Funding gaps, US$ billions by region Africa AsiaRest of World 59% 22 % 19% Gap in Asia could be bigger if domestic funding (in India, Indonesia, Philippines etc.) does not grow at projected level Smaller gaps in Rest of World but critical to fill for MDR response and quality TB care, esp. in Europe

Impact: numbers treated Millions treated for TBNumber treated for MDR-TB 17 million people treated for TB, ,000 treated for MDR-TB,

Impact: lives saved Status quo implies: 1.2 million lives lost Failure in MDR-response Failure to adopt rapid diagnostic tests Millions Lives saved (TB)Lives saved (MDR-TB) 0.2 million Status Quo Millions Status Quo

Key messages 1)In the 118 countries eligible to apply for Global Fund financing, US$14.5 billion is required for TB care and control 2014‒2016 2)There is potential to mobilize US$9.7 billion (67%) from domestic sources and US$0.6 billion from non-GF donor sources 3)Therefore, the anticipated demand for Global Fund financing is at least US$4.3 billion 2014–2016, or US$1.4 billion/year 4)MYTH TO DISPEL: «International funding not really needed for TB». In reality, gaps remain huge especially in low-income countries and Africa.